Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Assets (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Assets for 15 consecutive years, with $1.2 billion as the latest value for Q1 2026.

  • For Q1 2026, Assets fell 23.82% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $1.2 billion, down 23.82%, while the annual FY2025 figure was $1.3 billion, 22.0% down from the prior year.
  • Assets hit $1.2 billion in Q1 2026 for Agios Pharmaceuticals, down from $1.3 billion in the prior quarter.
  • Across five years, Assets topped out at $1.8 billion in Q3 2024 and bottomed at $773.1 million in Q2 2024.
  • Average Assets over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
  • Year-over-year, Assets tumbled 46.32% in 2022 and then skyrocketed 90.31% in 2025.
  • Agios Pharmaceuticals' Assets stood at $1.2 billion in 2022, then decreased by 24.35% to $937.1 million in 2023, then soared by 77.48% to $1.7 billion in 2024, then dropped by 22.0% to $1.3 billion in 2025, then dropped by 8.65% to $1.2 billion in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $1.2 billion, $1.3 billion, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.